Clinical Trial Update: Intranasal ALN-RSV01 Administered to Adult Volunteers Experimentally Inoculated With Respiratory Syncytial Virus [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating intranasal ALN-RSV01 in healthy adult volunteers experimentally inoculated with respiratory syncytial virus has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Syncytial Virus Infections

Drugs mentioned

• ALN-RSV01

Snippet

Sponsor: Alnylam Pharmaceuticals | Conditions: Respiratory Syncytial Virus Infections | Phase 2 | Status: COMPLETED